Neurocrine Biosciences (NBIX) reported a net loss of $24.0 million, or $0.28 loss per share, compared to a net loss of $13.4 million, or $0.18 loss per share, for the same period in 2014. For the six months ended June 30, 2015, the Company reported a net loss of $25.2… Read More
Dr. Joe Duarte is Chief Investment Strategist and Editor of Profit Catalyst Alert and Weekly Cash Machine. He has been a professional investor and independent analyst since 1990. He is a former Registered Investment Advisor and author of the Bestselling "Options Trading for Dummies," now in its 4th edition and several other books including "Market Timing for Dummies" and "Successful Biotech Investing". Although Joe's favorite areas of the market are technology and healthcare, he is a versatile investor who enjoys finding that hidden gem stock before the crowd, no matter what the sector. He is an original CNBC Market Maven, and is visible regularly on Stockcharts.TV. He has published articles on Marketwatch.com and has been widely quoted in the major media including The Wall Street Journal and Barron’s magazine.
Analyst Articles
[from the Portfolio Update in today’s issue of Smart Tech Investor]I am adding Dyax Corp. (DYAX) to the STI Medical Profits Portfolio because it is very close to having a real shot for FDA approval for a drug (DX-2390) that treats Hereditary Angioedema, a genetic disorder that occurs in… Read More
[from the Portfolio Update in today’s issue of Smart Tech Investor]I am adding Dyax Corp. (DYAX) to the STI Medical Profits Portfolio because it is very close to having a real shot for FDA approval for a drug (DX-2390) that treats Hereditary Angioedema, a genetic disorder that occurs in… Read More
- September 21, 2015
-
Download Issue
In this issue:The Big Picture: Biotech Sector Nears Major Decision PointIn Depth: New EBIS Pick – DYAX Corp (DYAX) – High Risk, High PotentialEBIS Portfolio Alerts: Alert: EBIS Portfolio Pricing Updates News Update: New FDA Commissioner Nominee Could Foster New Climate at AgencyThe Big Picture: Is The Biotech Sector Heading… Read More
In this issue:The Big Picture: Biotech Sector Nears Major Decision PointIn Depth: New EBIS Pick – DYAX Corp (DYAX) – High Risk, High PotentialEBIS Portfolio Alerts: Alert: EBIS Portfolio Pricing Updates News Update: New FDA Commissioner Nominee Could Foster New Climate at AgencyThe Big Picture: Is The Biotech Sector Heading… Read More
Our EBIS portfolio triggered some sell stops this past week. Repligen and Bio-Rad have been removed from the STI Medical Profits portfolio. However, due to some potential pricing issues in the Flash Crash on 8/24/15 some of the pricing may or may not have been accurate. Thus, we are not removing Neurocrine Biosciences… Read More
Our EBIS portfolio triggered some sell stops this past week. Repligen and Bio-Rad have been removed from the STI Medical Profits portfolio. However, due to some potential pricing issues in the Flash Crash on 8/24/15 some of the pricing may or may not have been accurate. Thus, we are not removing Neurocrine Biosciences… Read More
- August 17, 2015
-
Download Issue
In this issue:The Big Picture: Why Being Patient Matters In This MarketIn Depth: New EBS Pick – Greatbatch Inc. (GB) An Industrial Medical Equipment Turnaround Story with a TwistEBIS Portfolio Alerts: EBIS Portfolio Components Show Some Grace Under PressureNews Update: Research Stage Biotech Companies Feel the PinchThe biotech sector again… Read More
In this issue:The Big Picture: Why Being Patient Matters In This MarketIn Depth: New EBS Pick – Greatbatch Inc. (GB) An Industrial Medical Equipment Turnaround Story with a TwistEBIS Portfolio Alerts: EBIS Portfolio Components Show Some Grace Under PressureNews Update: Research Stage Biotech Companies Feel the PinchThe biotech sector again… Read More
We are not turning bearish on biotech at this point. But we do think it’s a good time to be patient and to consider some portfolio protection. Read More